Wandercraft acquired Ekso Bionics from a subsidiary of ChronoScale (Nasdaq: CHRN) on October 1, 2026, combining two medical exoskeleton developers into what the companies call the world's leading manufacturer in the category1,5. The deal was unanimously approved by both boards and signed and closed simultaneously2. Financial terms were not disclosed3.
The transaction merges Wandercraft's robotics and physical AI technology with Ekso Bionics' U.S. operations, clinical relationships, and commercial infrastructure built over roughly two decades. Wandercraft, based in France, holds an established presence in Europe, the Middle East, and Africa; Ekso Bionics is headquartered in the San Francisco Bay Area4.
Combined product fleet
The merged company will continue supporting four flagship devices spanning institutional rehabilitation and personal mobility. The institutional rehabilitation portfolio pairs Wandercraft's Atalante X with Ekso Bionics' EksoNR, which together operate at more than 700 rehabilitation and research centers worldwide. Both systems hold Food and Drug Administration clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis, and acquired brain injury.
On the personal-use side, the portfolio includes EVE, Wandercraft's hands-free, self-balancing personal exoskeleton, and Ekso Indego Personal, a modular wearable device. Both are intended for eligible individuals with spinal cord injuries. Wandercraft commercially launched EVE in the United States on September 17, 2026, after receiving FDA clearance[2]. For qualifying U.S. users, Medicare covers personal exoskeletons under its brace benefit category through HCPCS code K1007.
Physical AI and humanoid ambitions
Beyond medical exoskeletons, Wandercraft applies its robotics expertise to industrial humanoid systems, including CALVIN, an autonomous humanoid designed for heavy lifting and labor-intensive work. Wandercraft also operates the Walk in New York by Wandercraft rehabilitation center, where patients already receive exoskeleton-based training.
"We share a vision for how robotics can empower people whose mobility has been unfairly limited by injury or disease," Wandercraft CEO and co-founder Matthieu Masselin said. "By bringing together our products, teams, and clinical relationships on both sides of the Atlantic, we have an exceptional opportunity to expand access to robotic mobility worldwide".
ANALYSIS The acquisition gives Wandercraft immediate U.S. scale at a moment when its personal exoskeleton EVE has just entered the American market, pairing a new consumer-facing device with Ekso Bionics' established clinical installed base and reimbursement infrastructure. The deal also consolidates two of the sector's longest-running exoskeleton programs under one roof, concentrating physical AI and dynamic-balance robotics expertise that extends from rehabilitation hardware to the CALVIN industrial humanoid.